 Sinclair IS Pharma plc Annual report and accounts 2014
01
0
10
20
30
40
50
60
70
FY14 FY13 FY12 FY11 FY10 FY09
1
Annual revenue £m
EBITDA £m EBITDA Margin %
-6.0
-4.0
-2.0
0.0
2.0
4.0
6.0
8.0
10.0
12.0
FY14 FY13 FY12 FY11 FY10 FY09
EBITDA margin progression
-20%
-15%
-10%
-5%
0%
5%
10%
15%
20%
Highlights
2014
Financial highlights
Revenue increased by 15% to £63.6m (2013: £55.4m)
Like-for-like
1
 revenue growth of 4%
Adjusted EBITDA
2
 growth of 39% to £10.0m (2013: £7 .2m)
Operating loss falls by 88% to £1.8m (2013: £15.3m)
Loss per share falls to 1.2p (2013: 4.1p)
 Net debt at year end of £40.2m, 2.8x EBITDA on a pro forma basis  
including acquisitions
3
Operating highlights
Acquisitions of Obvieline SAS, AQTIS Medical BV and Silhouette Lift SL rapidly 
integrated to create a market-leading aesthetics portfolio
Dermatology 81% of revenues. International 40% of revenues
Flammacerium
®
 awarded US orphan drug status
1 Like-for-like (‘LFL’) revenues exclude product disposals, one-off licence fee income and currency fluctuations.
2  Adjusted EBITDA defined as earnings before interest, tax, depreciation, amortisation, share-based payments, exceptional items 
and loss from discontinued operations.
3  Pro forma EBITDA reflects a full year contribution for Obvieline SAS, AQTIS Medical BV and Silhouette Lift SL as if they were 
acquired on 1 July 2014.
1 FY09 excludes one-off licence fees of £6.3m.
